Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business UpdateGlobeNewsWire • 04/30/26
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026GlobeNewsWire • 04/23/26
KYMR Stock Up as FDA Grants Fast Track Designation to Asthma DrugZacks Investment Research • 04/14/26
Kymera: 'Strong Buy' On Continued Success With KT-621 In Th2-Driven DisordersSeeking Alpha • 04/13/26
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe AsthmaGlobeNewsWire • 04/13/26
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200Zacks Investment Research • 04/10/26
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual MeetingGlobeNewsWire • 03/28/26
Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/12/26
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual MeetingGlobeNewsWire • 03/10/26
Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss24/7 Wall Street • 03/10/26
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 02/26/26
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026GlobeNewsWire • 02/19/26
KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead CandidateZacks Investment Research • 01/30/26
Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology ProgramsGlobeNewsWire • 01/13/26